XVIVO | Academy

XVIVO Masterclass: Liver transplantation 2026



XVIVO is pleased to invite you to the XVIVO Masterclass Liver Transplantation 2026, taking place in Florence, Italy, on November 17-18, 2026.

Set in the historic heart of Florence, this exclusive 1.5-day masterclass brings together transplant clinicians and researchers for focused scientific exchange and peer-to-peer dialogue on the evolving world of liver machine perfusion.

XVIVO Masterclass aims to explore the full spectrum of liver machine perfusion – from established clinical evidence and current best practices to advanced applications and emerging approaches shaping the future of liver transplantation.

MAR-36486-v.1.0 2026.10

SESSION 1 – 17 NOV **9:00-12:30**

Expanding access in liver transplantation

How can we ensure that more patients benefit from the gift of organ donation? This session brings together perspectives on organ utilization, equity, machine perfusion, split liver transplantation, and transplant oncology to explore how innovation is expanding access to liver transplantation.

Moderator
Renato Romagnoli, A.O. Citta della Salute e della Scienza, Turin, IT

Speakers

Welcome to Florence - The Tuscan Experience in DCD
Chiara Lazzeri, Tuscany Regional Transplant Center, Florence, IT

Behind every organ - Donor family experiences and the emotional challenges of transplantation
Anja Bornø-Jensen, University of Copenhagen, Copenhagen, DK

Machine perfusion – Impact on organ utilization and emerging indications in liver transplant
Umberto Cillo, Azienda Ospedaliera Di Padova, Padova, IT

Equity and access – Expanding transplant opportunities
Mareike Franz, Magdeburg University Hospital, Magdeburg, DE

Machine perfusion against cancer – Facts and visions
Philipp Dutkowski, Inselspital - Universitätsspital Bern, Bern, CH

Perfusion for technical variant grafts - From refinement to new clinical standard
Xavier Muller, CHU Lyon, Lyon, FR

SESSION 2 – 17 NOV **13:30-15:45**

Emerging evidence and clinical experience

What have we learned from the first generation of machine perfusion studies? This session focuses on long-term trial outcomes, early clinical experiences, and cross-organ perspectives to examine how emerging evidence is informing clinical practice and guiding the next phase of innovation.

Moderator
Deniz Uluk, Medical University Vienna, Vienna, AT

Speakers

Clinical evidence across organs – Emerging lessons in machine perfusion Rodrigo Figueirdo, Freeman Hospital, Newcastle, UK

Cold-to-warm liver perfusion – Best of both worlds
Suomi Fouraschen, UMC Groningen, Groningen, NL

Warm flush versus recooling after MP – Early clinical experience Salvatore Gruttadauria, ISMETT, Palermo, IT

Evolution of HOPE in FRANCE - Past, present and future
Michel Rayar, CHU Nice, Nice, FR

Cold-to-warm without the switch – Simplifying sequential liver machine perfusion
Silke Bodewes, UMC Groningen, Groningen, NL

Long-term follow-up of the DHOPE-DCD trial
Rianne van Rijn, UMC Groningen, Groningen, NL

SESSION 3 – 17 NOV **16:15-18:15**

Building the modern liver transplant program

How can transplant programs scale-up to meet growing demand? This session explores practical strategies for implementing machine perfusion, building high-performing teams, and creating sustainable workflows that expand transplant activity while maintaining clinical excellence.

Moderator

Gabriel Oniscu, Karolinska University Hospital, Stockholm, Sweden

Speakers

HOPE as standard practice - Insights from one of the largest single-center HOPE cohorts
Severin Jacobi, LMU University Hospital Munich, Munchen, DE

Implementing prolonged HOPE to build a sustainable liver transplant program
Vincent de Meijer, UMC Groningen, Groningen, NL

Liver and let grow – From cardiothoracic roots to an organ perfusion program
Karlien Degezelle, UZ Leuven, Leuven, BE

NRP in modern transplantation – Where is the sweet spot?
Davide Ghinolfi, Azienda Ospedaliera Di Pisa, Pisa, IT

Scaling liver transplantation using an external perfusion service
Davide Chiappori, San Camillo Forlanini Hospital, Rome, IT

SESSION 4 – 18 NOV **8:30-10:40**

Next era of organ preservation and regeneration

Machine perfusion is evolving from a preservation technology into a platform for assessment, treatment, and regeneration. This session highlights cutting-edge research on prolonged perfusion, organ repair, organoid-based therapies, drug testing, and novel biomarkers, exploring how these innovations could transform the future of organ transplantation.

Moderator

Stefan Schneeberger, Innsbruck Medical University, Innsbruck, AT

Speakers

Clinical applications of human organoids – Opportunities for organ repair during machine perfusion
Luc Van der Laan, Erasmus MC, Rotterdam, NL

Liver regeneration with organ chips and ex vivo perfusion Carl Atkinson, Northwestern Medicine, Chicago, US

Alternative applications of ex vivo machine perfusion in transplantation Justin Steggerda, Cedars-Sinai Medical Center, Los Angeles, US

From hardware to software – Liver support during prolonged Ex situ NMP Amelia Hessheimer, Hospital Universitario La Paz, Madrid, ES

Utilizing HOPE for ex-vivo liver rescetion
Steve White, Freeman Hospital, Newcastle, UK

Validation of biomarkers in assessing DCD donor liver quality – The balance act between biliary complications and organ utilization Jeroen de Jonge, Erasmus MC, Rotterdam, NL

SESSION 5 – 18 NOV **11:10-12:40**

XVIVO Young Professionals Program abstract session

What perspectives will shape the future of liver transplantation? This session showcases participants in the XVIVO Young Professionals Program (YPP), providing a platform for emerging transplant clinicians and scientists to share research and engage with the broader transplant community. Together, these presentations will highlight the talent and innovation that will help shape the future of transplantation.

Moderator
Piotr Domagala, Medical University of Gdańsk, Gdansk, PL

Speakers

Microdialysis as a tool for liver assessment during ex situ machine perfusion – A pilot study
Henriette Vaage Valen, Oslo University Hospital, Oslo, NO

Flavin mononucleotide during hypothermic oxygenated machine perfusion as a predictor of long-term outcomes after liver transplantation
Moriz Riha, Vienna General Hospital, Vienna, AT

Establishing a reference framework for outcomes after machine-preserved liver transplantation in Europe (REFRAME-MP Study)
Sabrina Stimmeder, UMC Groningen, Groningen, NL

DCD V (donation after euthanasia) and the use of machine perfusion
Femke de Goeij, Erasmus MC, Rotterdam, NL

Hypothermic oxygenated perfusion after NRP to extend donor selection criteria in cDCD liver transplantation – A French multicenter study
Natacha Boulanger, CHU Lyon, Lyon, FR

When hope is not enough - A model to predict outcome of liver grafts treated by hypothermic oxygenated machine perfusion
Nicola de Stefano, Molinette Hospital, Turin, IT

SESSION 6 – 18 NOV **12:40-14:00**

The economic impact of machine perfusion

What is the true value of machine perfusion? This session examines the economic evidence behind perfusion technologies, exploring health economic models, technology assessments, hospital outcomes and real-world data to understand their impact on healthcare systems and transplant practices.

Moderator
Shennen Mao, Mayo Clinic Jacksonville, Jacksonville, FL, US

Speakers

The machine perfusion revolution – What are the cost? – What are the savings?
Markus Selzner, University Health Network, Toronto, CA

Machine perfusion in liver transplantation – 2026 view on cost-effectiveness
Colin Wilson, Freeman Hospital, Newcastle, UK

Demonstrating value beyond evidence – The Belgian path to reimbursing machine perfusion
Diethard Monbaliu, UZ Leuven, Leuven, BE